Skip to main content


Advances in Therapy

Advances in Therapy OnlineFirst articles

22.02.2020 | Original Research Open Access

What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is one of the most prevalent autoimmune chronic inflammatory diseases [ 1 , 2 ]. If sub-optimally treated, RA can lead to joint damage [ 2 ], causing different degrees of disability, loss of quality of life (QoL) and even …

21.02.2020 | Review Open Access

Safety and Efficacy of YAG Laser Vitreolysis for the Treatment of Vitreous Floaters: An Overview

Emerging evidence has suggested that the entoptic phenomena associated with vitreous opacities (i.e. vitreous floaters) are more bothersome than previously believed. In addition, the prevalence of vitreous floaters is likely increasing due to the …

20.02.2020 | Original Research Open Access

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses

Daratumumab is a human immunoglobulin Gκ (IgGκ) monoclonal antibody targeting CD38 with a direct on-tumor [ 1 – 4 ] and immunomodulatory [ 5 – 7 ] mechanism of action. Daratumumab 16 mg/kg administered intravenously (IV) demonstrates activity as …

19.02.2020 | Original Research Open Access

Nonselective β-Blockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study

Liver cirrhosis often leads to serious complications [ 1 ], such as liver failure [ 2 ], hepatic encephalopathy [ 3 ], ascites [ 4 ], and spontaneous portosystemic shunts [ 5 ]. Recent evidence suggests that portal venous system thrombosis (PVT) is …

18.02.2020 | Original Research Open Access

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study

Elevated intraocular pressure (IOP) is the most important modifiable risk factor for development and progression of open-angle glaucoma (OAG) [ 1 ]. A wealth of data has demonstrated that IOP reduction is associated with slowing of disease …

Aktuelle Ausgaben

Über diese Zeitschrift

Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.

Advances in Therapy is of interest to a broad audience of researchers, industry and healthcare professionals, receiving submissions from all over the world, and publishes original research and authoritative reviews focusing on new and existing therapies and interventions, areas of unmet need and general topics of interest to the medical community.

Moving forward from traditional publishing, Advances in Therapy offers a range of additional features designed to increase visibility and readership. Each paper is accompanied by a bulleted slide summary, giving a time-efficient overview of the content to a wider readership. Articles also have the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are open access and are peer reviewed to the same high standard as the article itself.

Upon acceptance of your article for publication, you will be required to pay an article processing charge of £420/$660 per typeset page. Additionally, Advances in Therapy offers an open access option for all articles submitted to the journal. If you choose open access publication you will be required to pay an additional fee of £2000/$3000 upon acceptance of your article.

Please note: Advances in Therapy's open access articles are published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here:

For more information about the journal, please contact or see the News page for the latest journal offers.

Weitere Informationen

Neu im Fachgebiet Innere Medizin

Meistgelesene Bücher aus der Inneren Medizin

2017 | Buch

Rheumatologie aus der Praxis

Entzündliche Gelenkerkrankungen – mit Fallbeispielen

Dieses Fachbuch macht mit den wichtigsten chronisch entzündlichen Gelenk- und Wirbelsäulenerkrankungen vertraut. Anhand von über 40 instruktiven Fallbeispielen werden anschaulich diagnostisches Vorgehen, therapeutisches Ansprechen und der Verlauf …

Rudolf Puchner

2016 | Buch

Ambulant erworbene Pneumonie

Was, wann, warum – Dieses Buch bietet differenzierte Diagnostik und Therapie der ambulant erworbenen Pneumonie zur sofortigen sicheren Anwendung. Entsprechend der neuesten Studien und Leitlinien aller wichtigen Fachgesellschaften.

Santiago Ewig

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin